NEW YORK, Feb. 08, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces
the publication of an editorial featuring PreveCeutical Medical Inc. (OTCQB:PRVCF) (CSE:PREV) (FSE:18H), a client
of NNW and health sciences company that develops innovative preventive therapies utilizing organic and nature identical products.
To view the full publication, titled “Investment Opportunities in Advanced Bioengineered Drug Delivery,” visit: LINK
PreveCeutical Medical (CSE:PREV) (OTCQB:PRVCF) (FSE:18H), a preventive health sciences
company initiating a broad spectrum of preventive and curative therapies, is engineering what it believes to be the world’s first
nose-to-brain hydrogel platform. Following several years of research and development by PreveCeutical’s chief research officer, Dr.
Harendra Parekh, Ph.D., the company’s novel sol-gel technology is designed for superior time-released delivery of cannabinoid
(CBD)-based medications. Bypassing typical delivery techniques, this nasal spray formulation is meticulously engineered to rapidly
gel and deliver drugs in a controlled fashion across target tissue, which in the case of nose-to-brain delivery is the olfactory
mucosal epithelium within the nasal cavity.
Conventional drug delivery, whether through oral or injectable mediums, moves drugs into the bloodstream where
they are then passed through the liver. The drugs are unable to directly impact the targeted area as the liver first filters then
metabolizes the drugs, which also affects release times and reduces potency. In a potentially transformative technique of drug
delivery, PreveCeutical’s platform circumvents the blood-brain barrier and liver through application directly onto nasal mucosal
tissue. The blood-brain barrier has long challenged effective medicine delivery due to the filtering mechanism of the capillaries
that carry blood to the brain and block the passage of certain substances.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing
organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five
research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a
Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment
of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl
and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential
minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information visit www.PreveCeutical.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of
wire services via NetworkWire to reach all target markets, industries and demographics in the most effective
manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure
maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array
of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors,
consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its
clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more
information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever
published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain
as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers
are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the
date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties
identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's
actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
